News
All news from Vismederi Holding
VisMederi Group at the World Vaccine Congress in Washington, D.C.
VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. This congress served as an exceptional platform for engaging with leaders across the entire...
VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times
VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times, securing the 346th position among Europe's fastest-growing companies! This honor not only signifies our success and growth in the research and development field...
VisMederi at the University of Siena’s prestigious event “USiena Game”
Elisa Mennitto, Chief Facilities and Lab Officer, represented VisMederi at the University of Siena's prestigious event "USiena Game". Addressing over 90 students from various schools, Elisa showcased the innovative spirit and cutting-edge research at the heart of...
Our manuscript “#CEPI Centralized Laboratory Network: a qualification analysis” has been published in The Lancet Microbe Online
Our manuscript "#CEPI Centralized Laboratory Network: a qualification analysis" has been published in The Lancet Microbe Online. This publication marks a significant contribution to the global scientific community, showcasing our latest advancements in vaccine...
New Research Highlights the Importance of Vaccinations in Leukemia Patients
VisMederi is excited to share a significant breakthrough in medical research conducted in collaboration with Landspítali University of Reykjavík, Iceland. Our latest study, focusing on the immunological responses of leukemia patients to vaccinations, reveals...
Making Strides in Global Health: VisMederi at the World Bio Summit 2023!
VisMederi, represented by the Founder and CSO Prof. Emanuele Montomoli, played a pivotal role at the esteemed World Bio Summit 2023 in Seoul. This landmark event united over 200 luminaries, from government officials to biopharma leaders, to forge paths in pandemic...